AVYIA
Free Consultation
Call Us
AVYIA
Free Consultation
Call Now

Tirzepatide

Weight loss

Hormone-like Action

Reduce Appetite

Fat Utilization

Metabolic
Boost

Insulin
Production

Tirzepatide is a medication classified as a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. It is primarily used for managing type 2 diabetes, promoting weight loss, and reducing cardiovascular risks in certain population  

Compounded Tirzepatide

Weeks 1-4:  2.5 mg once weekly

Weeks 5-8:  5 mg once weekly

Weeks 9-12:  7.5 mg once weekly

Weeks 13-16:  15 mg once weekly

Injection – once a week

Oral – daily

Injectable compounded Tirzepatide:

  1. Wash your hands and clean the injection site (abdomen, thigh, or upper arm) with an alcohol swab. Draw the prescribed dose into a new syringe from a vial.
  2. Pinch the skin at the cleaned site, insert the needle at a 90-degree angle, and push the plunger slowly to inject the medication. Hold for 5-10 seconds before removing the needle.
  3. Discard the used needle/syringe in a sharps disposal container and store the remaining medication in the refrigerator if needed.


Oral compounded Tirzepatide drops:

  1. Wash your hands before handling the medication.
  2. Measure the prescribed dose using the provided oral syringe, and place the liquid under your tongue. Hold the liquid under your tongue for 30-60 seconds before swallowing.
  3. Do not eat or drink anything for at least 15 minutes after taking the dose to allow proper absorption. Store the medication as instructed, usually in a cool place or refrigerator.

Starting $199 First Month | Prescription Required

Free Consultation
Lost-2

Overview

Two out of three Americans are either overweight or obese. Today, approximately 40% of Americans are considered obese, and it is projected that half of Americans will be obese by 2030. World-wide, the WHO has declared obesity as an epidemic since 1997, and the problem has only gotten worse since then. Obesity increases the likelihood of developing other diseases, such as diabetes type II, heart disease, cancer, and many other ailments. Obesity-related deaths in the U.S. number in the hundreds of thousands every year. However, a recent breakthrough in the treatment of weight loss was discovered. The class of drugs called the glucagon-like peptide-1 receptor agonists, or GLP-1 agonists, has been gaining in popularity for its ability to provide significant weight loss with tolerable or minimal side effects.

Tirzepatide is the generic version of the brand-named Mounjaro®. Tirzepatide and other GLP-1 agonists such as Semaglutide and Ozempic®, work by regulating blood sugar levels and suppressing appetite at the brain. GLP-1’s was originally prescribed for diabetic patients, however, patients on these drugs also reported significant weight loss. Thus, study after study was conducted to assess the safety and efficacy of these drugs for the treatment of obesity. Today, Tirzepatide and other GLP-1 agonists are commonly prescribed off-label after repeated confirmation of its efficacy to shed weight, and safety profile.

Why Compounded Tirzepatide or Generic Drugs?

Contrary to popular belief and media reports, compounded medications from reputable and vetted compounding pharmacies are safe and effective. They provide the same desired effects as their brand-named counter parts for a fraction of the costs. Currently, there is a massive demand for brand-named GLP-1 agonists, resulting in frequent supply shortages for patients. Compounded medications fill in those shortage gaps, while providing affordable options for patients.

Who is Tirzepatide For?

  • Individuals who are obese, with a body mass index, or BMI of 30 or more
  • Patients with a cardiovascular comorbidity, such as high blood pressure, high cholesterol, heart disease, or stroke, and have a BMI of 27 or more, are eligible for treatment.
  • Diabetics, regardless of obesity, are also eligible for treatment, typically concurrently with other diabetes medications

How is Tirzepatide Administered?

Tirzepatide is a once weekly injection taken overs weeks and months for the sustainment of weight loss and treating diabetes. The dosage of the medication is generally increased in the first several months, until a maximum dose is achieved. Your healthcare provide will guide you every step of the way and teach you how to inject yourself with these medications. Subcutaneous injections are administered superficially in a fatty part of the body, such as the belly, buttocks, or back of the arm.

What’s The Dosing Schedule Look Like?

Weeks 1-4: 0.25 mg once weekly
Weeks 5-8: 0.5 mg once weekly
Weeks 9-12: 1 mg once weekly
Weeks 13-16: 1.7 mg once weekly
Weeks 17+: 2.4 mg once weekly

Side Effects:

The most common side effect of Semaglutide is gastrointestinal related, occurring in approximately 10% of patients or more. Mild nausea appears to be the most common of the GI side-effects. Loss of appetite is also commonly reported, but likely is more of a “feature” of the drug, attributed to the GLP-1’s mechanism of action to suppress appetite. Diarrhea, abdominal pain, and constipation may also occur with some patients. Most patients report these side effects to dissipate or become milder with time, as the body adjusts during the first steps of titrating the medication. In rare instances, there have been reported gallbladder disease, pancreatitis and kidney injury. It is important to stay hydrated while on GLP-1’s to prevent these issues from occurring. Patients on GLP-1’s must stop their use of the drug if these, and other adverse reactions occur.

Drug Considerations:

AVYIA recommends a comprehensive exercise and nutrition regime when taking Semaglutide and other GLP-1 agonist medications. While significant weight loss is a desired effect, part of that weight lost is from muscle mass unfortunately. Regular strength and weight training maintains proper muscle preservation or growth, while further enhancing fat loss. A diet rich in protein, and sparse in artificial sugars and processed carbohydrates is also recommended while on GLP-1 agonists. Regular exercise and a proper diet further help with weight loss while maintaining lean muscle mass.

Contraindications:

  • As with any new drug, individuals who have had an allergic reaction, sensitivity, or adverse effect from a prior GLP-1 agonist drug, such as Tirzepatide (Mounjaro), Dulaglutide (Trulicity), Exenatide (Bydureon, Byetta,), Liraglutide (Victoza, Saxenda), Lixisenatide (Adlyxin).
  • Individuals who currently are suffering from, or have a history of anorexia, bulimia, or other eating disorder that puts them at a nutrient deficiency risk.
  • Women who are pregnant, or are trying to get pregnant, should not start or be on Semaglutide.
  • Patients whom have a history, or family history of medullary thyroid cancer or multiple endocrine neoplasia (MEN2), should not start or be on Semaglutide.
  • Individuals with a body mass index (BMI) of less than 27.
  • Patients with kidney disease, pancreatitis, gallbladder disease, and diabetic retinopathy.

How Does Semaglutide Compare To Other GLP-1 Agonists?

Compared to Tirzepatide, Semaglutide is lower in month-to-month costs. While both drugs have shown to significantly reduce weight, Tirzepatide is likely to yield more weight loss with similar treatment regimes. In comparative studies, Tirzepatide has shown to have milder side effects. However, most patients on Semaglutide tolerate the already mild GI side effects after a short duration of treatment

  • Bioavailability: 80%
  • Half-Life: approximately 5 days
  • Peak Onset: 8 to 72 hours

AVYIA

Discover the convenience of Telehealth, mail-prescription and at-home visits. We offer safe and effective medical services in Washington State.

  • Business Address :
  • 600 1st Avenue Suit 102 #2268,
  • Seattle Washington 98104
  • Phone : (206) 865-7865
  • Email : info@avyia.com
Facebook Twitter Youtube

Ketamine

IV Therapy

Menu

Weight Loss

Disclosure